Masahiro Fujita

Masahiro Fujita

Auto-generated profile, based on publicly available information

Masahiro Fujita

Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
RIRobert B Innis
Robert B Innis
VCVincent J Cunningham
Vincent J Cunningham
JDJacques Delforge
Jacques Delforge
MFMasahiro Fujita
Masahiro Fujita
Albert GjeddeAlbert Gjedde
Albert Gjedde
RCRichard E Carson
Richard E Carson
An international group of experts in pharmacokinetic modeling recommends a consensus nomenclature to describe in vivo molecular imaging of reversibly binding radioligands.

13 December 2010 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
DODavid R.J. Owen
David R.J. Owen
RGRoger N. Gunn
Roger N. Gunn
EREugenii A. Rabiner
Eugenii A. Rabiner
IBIdriss Bennacef
Idriss Bennacef
MFMasahiro Fujita
Masahiro Fujita
CPChristine A. Parker
Christine A. Parker
11C-PBR28 PET can detect the 18-kDa translocator protein (TSPO) expressed within macrophages. However, quantitative evaluation of the signal in brain tissue from donors with multiple sclerosis (MS) shows that PBR28 binds the TSPO with high affinity (binding affinity [Ki], ∼4 nM), low affinity (Ki, ∼200 nM), or mixed affinity (2 sites with Ki, ∼4 nM and ∼300 nM). Our study tested whether similar binding behavior could be detected in brain tissue from donors with no history of neurologic disease, with TSPO-binding PET ligands other than 11C-PBR28, for TSPO present in peripheral blood, and with human brain PET data acquired in vivo with 11C-PBR28. Methods: The affinity of TSPO ligands was measured in the human brain postmortem from donors with a history of MS (n = 13), donors without any history of neurologic disease (n = 20), and in platelets from healthy volunteers (n = 13). Binding potential estimates from thirty-five 11C-PBR28 PET scans from an independent sample of healthy volunteers were analyzed using a gaussian mixture model. Results: Three binding affinity patterns were found in brains from subjects without neurologic disease in similar proportions to those reported previously from studies of MS brains. TSPO ligands showed substantial differences in affinity between subjects classified as high-affinity binders (HABs) and low-affinity binders (LABs). Differences in affinity between HABs and LABs are approximately 50-fold with PBR28, approximately 17-fold with PBR06, and approximately 4-fold with DAA1106, DPA713, and PBR111. Where differences in affinity between HABs and LABs were low (∼4-fold), distinct affinities were not resolvable in binding curves for mixed-affinity binders (MABs), which appeared to express 1 class of sites with an affinity approximately equal to the mean of those for HABs and LABs. Mixed-affinity binding was detected in platelets from an independent sample (HAB, 69%; MAB, 31%), although LABs were not detected. Analysis of 11C-PBR28 PET data was not inconsistent with the existence of distinct subpopulations of HABs, MABs, and LABs. Conclusion: With the exception of 11C-PK11195, all TSPO PET ligands in current clinical application recognize HABs, LABs, and MABs in brain tissue in vitro. Knowledge of subjects’ binding patterns will be required to accurately quantify TSPO expression in vivo using PET.

3 August 2011 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
PZPaolo Zanotti-Fregonara
Paolo Zanotti-Fregonara
KCKewei Chen
Kewei Chen
JLJeih-San Liow
Jeih-San Liow
MFMasahiro Fujita
Masahiro Fujita
RIRobert B Innis
Robert B Innis
Quantitative positron emission tomography (PET) brain studies often require that the input function be measured, typically via arterial cannulation. Image-derived input function (IDIF) is an elegant and attractive noninvasive alternative to arterial sampling. However, IDIF is also a very challenging technique associated with several problems that must be overcome before it can be successfully implemented in clinical practice. As a result, IDIF is rarely used as a tool to reduce invasiveness in patients. The aim of the present review was to identify the methodological problems that hinder widespread use of IDIF in PET brain studies. We conclude that IDIF can be successfully implemented only with a minority of PET tracers. Even in those cases, it only rarely translates into a less-invasive procedure for the patient. Finally, we discuss some possible alternative methods for obtaining less-invasive input function.

1 February 2010 in NeuroImage
Verified
Journal Article
Closed access
WKWilliam C. Kreisl
William C. Kreisl
MFMasahiro Fujita
Masahiro Fujita
YFYota Fujimura
Yota Fujimura
NKNobuyo Kimura
Nobuyo Kimura
KJKimberly J. Jenko
Kimberly J. Jenko
RIRobert B. Innis
Robert B. Innis

1 May 2006 in Biological Psychiatry
Verified
Journal Article
Closed access
VCVanessa L. Cropley
Vanessa L. Cropley
MFMasahiro Fujita
Masahiro Fujita
RIRobert B. Innis
Robert B. Innis
PNPradeep J. Nathan
Pradeep J. Nathan

12 March 2015 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
CLChul Hyoung Lyoo
Chul Hyoung Lyoo
MIMasamichi Ikawa
Masamichi Ikawa
JLJeih-San Liow
Jeih-San Liow
SZSami S. Zoghbi
Sami S. Zoghbi
CMCheryl L. Morse
Cheryl L. Morse
WKWilliam Charles Kreisl
William Charles Kreisl
Alzheimer disease (AD) is associated with an increase in the brain of the 18-kDa translocator protein (TSPO), which is overexpressed in activated microglia and reactive astrocytes. Measuring the density of TSPO with PET typically requires absolute quantitation with arterial blood sampling, because a reference region devoid of TSPO does not exist in the brain. We sought to determine whether a simple ratio method could substitute for absolute quantitation of binding with 11C-PBR28, a second-generation radioligand for TSPO. Methods: 11C-PBR28 PET imaging was performed in 21 healthy controls, 11 individuals with mild cognitive impairment, and 25 AD patients. Group differences in 11C-PBR28 binding were compared using 2 methods. The first was the gold standard method of calculating total distribution volume (VT), using the 2-tissue-compartment model with the arterial input function, corrected for plasma-free fraction of radiotracer (fP). The second method used a ratio of brain uptake in target regions to that in cerebellum—that is, standardized uptake value ratio (SUVR). Results: Using absolute quantitation, we confirmed that TSPO binding (VT/fP) was greater in AD patients than in healthy controls in expected temporoparietal regions and was not significantly different among the 3 groups in the cerebellum. When the cerebellum was used as a pseudo-reference region, the SUVR method detected greater binding in AD patients than controls in the same regions as absolute quantification and in 1 additional region, suggesting SUVR may have greater sensitivity. Coefficients of variation of SUVR measurements were about two-thirds lower than those of absolute quantification, and the resulting statistical significance was much higher for SUVR when comparing AD and healthy controls (e.g., P < 0.0005 for SUVR vs. P = 0.023 for VT/fP in combined middle and inferior temporal cortex). Conclusion: To measure TSPO density in AD patients and control subjects, a simple ratio method SUVR can substitute for, and may even be more sensitive than, absolute quantitation. The SUVR method is expected to improve subject tolerability by allowing shorter scanning time and not requiring arterial catheterization. In addition, this ratio method allows smaller sample sizes for comparable statistical significance because of the relatively low variability of the ratio values.